menu ☰
menu ˟

[Comment] New-generation JAK inhibitors: how selective can they be?

13 Jun 2018

Almost 20 years into the biologics era, an unmet need exists for treating patients with rheumatoid arthritis and other inflammatory diseases who either do not tolerate, do not respond to, or cannot afford effective but costly biologic medicines. Also 20 years ago, the small family of Janus kinases (or tyrosine-protein kinase JAK; JAKs) were discovered, and have since been harnessed for treating and understanding both malignancies and inflammatory diseases.

Click here to view the full article which appeared in The Lancet